Overview of treatment of superficial bladder cancer.

M. S. Soloway

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Seventy per cent to 80 per cent of patients with bladder cancer will have their initial tumor confined to the mucosa (Stage Ta or Tcis, carcinoma in situ) or lamina propria (Stage T1), and at least 50 per cent of them will have a true recurrence or new recurrence despite resection of their initial tumor. If the tumor is of low grade and confined to the mucosa, intravesical chemotherapy might be considered either as treatment if the neoplasm is too extensive to resect completely or if multiple prior endoscopic resections have failed, or, alternatively, as prophylaxis against a subsequent tumor after complete endoscopic removal of the existing neoplasm. Thiotepa, until recently the most commonly used agent, completely eradicates all obvious tumor in approximately 30 per cent of patients, and it is effective in preventing subsequent tumor. Myelosuppression occurs in up to 20 per cent of patients receiving this agent, so careful monitoring of the white blood cell and platelet counts is mandatory. Mitomycin has low risk of myelosuppression and is effective in both the treatment and prophylaxis of superficial bladder cancer; the complete response rate is the same whether patients had an initial low-grade papillary or high-grade tumor (carcinoma in situ). Doxorubicin hydrochloride and bacillus Calmette-Guérin (BCG) are other agents that have been used for intravesical therapy. Chemical cystitis, the primary side effect of doxorubicin, has caused discontinuation of treatment in 15 per cent to 20 per cent of patients. The efficacy of doxorubicin varies among those reporting its use. BCG has been shown to be effective in both treatment and prophylaxis, with response rates similar to those reported for mitomycin; however, a comparative trial has not been performed. There is a need to standardize the potency of each BCG vial and to determine fully the necessity of concomitant intradermal administration.

Original languageEnglish
Pages (from-to)18-26
Number of pages9
JournalUrology
Volume26
Issue number4 Suppl
StatePublished - Oct 1 1985

Fingerprint

Urinary Bladder Neoplasms
Neoplasms
Doxorubicin
Bacillus
Mucous Membrane
Therapeutics
Carcinoma in Situ
Mitomycin
Thiotepa
Recurrence
Cystitis
Proxy
Platelet Count
Leukocyte Count
Drug Therapy

ASJC Scopus subject areas

  • Urology

Cite this

Soloway, M. S. (1985). Overview of treatment of superficial bladder cancer. Urology, 26(4 Suppl), 18-26.

Overview of treatment of superficial bladder cancer. / Soloway, M. S.

In: Urology, Vol. 26, No. 4 Suppl, 01.10.1985, p. 18-26.

Research output: Contribution to journalArticle

Soloway, MS 1985, 'Overview of treatment of superficial bladder cancer.', Urology, vol. 26, no. 4 Suppl, pp. 18-26.
Soloway MS. Overview of treatment of superficial bladder cancer. Urology. 1985 Oct 1;26(4 Suppl):18-26.
Soloway, M. S. / Overview of treatment of superficial bladder cancer. In: Urology. 1985 ; Vol. 26, No. 4 Suppl. pp. 18-26.
@article{252d07c7de844226a85995d93a5370c6,
title = "Overview of treatment of superficial bladder cancer.",
abstract = "Seventy per cent to 80 per cent of patients with bladder cancer will have their initial tumor confined to the mucosa (Stage Ta or Tcis, carcinoma in situ) or lamina propria (Stage T1), and at least 50 per cent of them will have a true recurrence or new recurrence despite resection of their initial tumor. If the tumor is of low grade and confined to the mucosa, intravesical chemotherapy might be considered either as treatment if the neoplasm is too extensive to resect completely or if multiple prior endoscopic resections have failed, or, alternatively, as prophylaxis against a subsequent tumor after complete endoscopic removal of the existing neoplasm. Thiotepa, until recently the most commonly used agent, completely eradicates all obvious tumor in approximately 30 per cent of patients, and it is effective in preventing subsequent tumor. Myelosuppression occurs in up to 20 per cent of patients receiving this agent, so careful monitoring of the white blood cell and platelet counts is mandatory. Mitomycin has low risk of myelosuppression and is effective in both the treatment and prophylaxis of superficial bladder cancer; the complete response rate is the same whether patients had an initial low-grade papillary or high-grade tumor (carcinoma in situ). Doxorubicin hydrochloride and bacillus Calmette-Gu{\'e}rin (BCG) are other agents that have been used for intravesical therapy. Chemical cystitis, the primary side effect of doxorubicin, has caused discontinuation of treatment in 15 per cent to 20 per cent of patients. The efficacy of doxorubicin varies among those reporting its use. BCG has been shown to be effective in both treatment and prophylaxis, with response rates similar to those reported for mitomycin; however, a comparative trial has not been performed. There is a need to standardize the potency of each BCG vial and to determine fully the necessity of concomitant intradermal administration.",
author = "Soloway, {M. S.}",
year = "1985",
month = "10",
day = "1",
language = "English",
volume = "26",
pages = "18--26",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4 Suppl",

}

TY - JOUR

T1 - Overview of treatment of superficial bladder cancer.

AU - Soloway, M. S.

PY - 1985/10/1

Y1 - 1985/10/1

N2 - Seventy per cent to 80 per cent of patients with bladder cancer will have their initial tumor confined to the mucosa (Stage Ta or Tcis, carcinoma in situ) or lamina propria (Stage T1), and at least 50 per cent of them will have a true recurrence or new recurrence despite resection of their initial tumor. If the tumor is of low grade and confined to the mucosa, intravesical chemotherapy might be considered either as treatment if the neoplasm is too extensive to resect completely or if multiple prior endoscopic resections have failed, or, alternatively, as prophylaxis against a subsequent tumor after complete endoscopic removal of the existing neoplasm. Thiotepa, until recently the most commonly used agent, completely eradicates all obvious tumor in approximately 30 per cent of patients, and it is effective in preventing subsequent tumor. Myelosuppression occurs in up to 20 per cent of patients receiving this agent, so careful monitoring of the white blood cell and platelet counts is mandatory. Mitomycin has low risk of myelosuppression and is effective in both the treatment and prophylaxis of superficial bladder cancer; the complete response rate is the same whether patients had an initial low-grade papillary or high-grade tumor (carcinoma in situ). Doxorubicin hydrochloride and bacillus Calmette-Guérin (BCG) are other agents that have been used for intravesical therapy. Chemical cystitis, the primary side effect of doxorubicin, has caused discontinuation of treatment in 15 per cent to 20 per cent of patients. The efficacy of doxorubicin varies among those reporting its use. BCG has been shown to be effective in both treatment and prophylaxis, with response rates similar to those reported for mitomycin; however, a comparative trial has not been performed. There is a need to standardize the potency of each BCG vial and to determine fully the necessity of concomitant intradermal administration.

AB - Seventy per cent to 80 per cent of patients with bladder cancer will have their initial tumor confined to the mucosa (Stage Ta or Tcis, carcinoma in situ) or lamina propria (Stage T1), and at least 50 per cent of them will have a true recurrence or new recurrence despite resection of their initial tumor. If the tumor is of low grade and confined to the mucosa, intravesical chemotherapy might be considered either as treatment if the neoplasm is too extensive to resect completely or if multiple prior endoscopic resections have failed, or, alternatively, as prophylaxis against a subsequent tumor after complete endoscopic removal of the existing neoplasm. Thiotepa, until recently the most commonly used agent, completely eradicates all obvious tumor in approximately 30 per cent of patients, and it is effective in preventing subsequent tumor. Myelosuppression occurs in up to 20 per cent of patients receiving this agent, so careful monitoring of the white blood cell and platelet counts is mandatory. Mitomycin has low risk of myelosuppression and is effective in both the treatment and prophylaxis of superficial bladder cancer; the complete response rate is the same whether patients had an initial low-grade papillary or high-grade tumor (carcinoma in situ). Doxorubicin hydrochloride and bacillus Calmette-Guérin (BCG) are other agents that have been used for intravesical therapy. Chemical cystitis, the primary side effect of doxorubicin, has caused discontinuation of treatment in 15 per cent to 20 per cent of patients. The efficacy of doxorubicin varies among those reporting its use. BCG has been shown to be effective in both treatment and prophylaxis, with response rates similar to those reported for mitomycin; however, a comparative trial has not been performed. There is a need to standardize the potency of each BCG vial and to determine fully the necessity of concomitant intradermal administration.

UR - http://www.scopus.com/inward/record.url?scp=0022137169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022137169&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 18

EP - 26

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4 Suppl

ER -